(Q37833895)

24 August 2017

1 reference

title

Vaptans for the treatment of hyponatremia (English)

1 reference

24 August 2017

Gary L Robertson

1

1 reference

24 August 2017

publication date

1 February 2011

1 reference

Nature Reviews Endocrinology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

151-161

1 reference

Neurogenic disorders of osmoregulation

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Water and sodium retention in edematous disorders: role of vasopressin and aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Antidiuretic hormone. Normal and disordered function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Mechanisms of cell volume regulation in hypo-osmolality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Brain volume regulation in response to hypo-osmolality and its correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

The osmoregulation of vasopressin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Dilution and concentration of the urine and the action of antidiuretic hormone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.229

Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men

31 March 2020

1 reference

12 December 2020

The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects.

1 reference

12 December 2020

Lixivaptan (American Home Products).

1 reference

12 December 2020

Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin

1 reference

12 December 2020

An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist

1 reference

12 December 2020

The use of vasopressin assays in physiology and pathophysiology.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.229

1 reference

24 August 2017

1 reference